PFE · 8-K · 20261103PR000125

Restructuring Charges

PFIZER INC · 2026-11-03 · Importance 77 · Surprise 82 · From source text

Third-quarter 2026 restructuring charges and certain acquisition-related costs totaled $791 million, compared with $286 million in the prior-year quarter. Within that total, cost-reduction initiative charges were $742 million, compared with $236 million a year earlier, and primarily reflected employee termination costs under the enterprise-wide cost realignment program. First-nine-month restructuring and acquisition-related costs were $1.347 billion, up 43% from $945 million. The nine-month cost-reduction initiative component was $1.167 billion, compared with $771 million in 2025.

Key facts

• Pfizer recorded $742 million of third-quarter 2026 restructuring charges related to cost-reduction initiatives, compared with $236 million in third-quarter 2025; the 2026 charges primarily represented employee termination costs associated with its enterprise-wide cost realignment program. source
• Pfizer’s reported restructuring charges and certain acquisition-related costs totaled $791 million in third-quarter 2026, compared with $286 million in third-quarter 2025. source
• Pfizer’s cost-reduction and productivity initiatives, including potential future phases, require upfront costs and may fail to deliver anticipated benefits or cause unexpected costs and organizational disruption. source

Impact estimates